Image credit- shutterstock
Novotech, a leading global biotech CRO and full-service clinical research organisation, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets.
The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, FDA-aligned protocol development, US-based scientific expertise, and international partnering opportunities.
Japan is one of the world’s largest and most advanced pharmaceutical markets, supported by a sophisticated research base and a rapidly evolving biotech sector. As more Japanese biopharma companies look to expand beyond domestic development and bring novel therapies to global markets, Novotech’s expanded presence in Tokyo strengthens its ability to support cross-border clinical trials and connect sponsors across Asia-Pacific, the United States, and Europe.
Novotech’s global operating model is particularly well aligned to the needs of emerging and growth-stage biopharma companies, providing flexible, high-quality clinical development support without the complexity of managing multiple regional providers. The company brings deep experience across therapeutic areas including oncology, rare diseases, central nervous system disorders, infectious diseases, immunology, and advanced therapies, supported by strong regulatory, scientific, and operational expertise across major clinical trial markets.
